Tocilizumab and pegfilgrastim
12 April 2013
PHARMAC is seeking feedback on a proposal to list pegfilgrastim (Neulastim) for prevention of neutropenia in patients undergoing cancer chemotherapy, and tocilizumab (Actemra) for systemic juvenile idiopathic arthritis, from 1 July 2013, through a provisional agreement with Roche Products (NZ) Limited.
PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by 5:00 pm on Monday 29 April 2013 to:
Senior Therapeutic Group Manager
Fax: 04 460 4995
Post: PO Box 10 254, Wellington 6143.
All feedback received before the closing date will be considered by PHARMAC’s Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.